Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...